DOCSLIB.ORG

Slow Resolution of Clinically Active Trachoma Following Successful Mass Antibiotic Treatments

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Slow Resolution of Clinically Active Trachoma Following Successful Mass Antibiotic Treatments LETTERS RESEARCH LETTERS Clinically active trachoma Chlamydial infection 100 Slow Resolution of Clinically Active 80 Trachoma Following Successful Mass 60 Antibiotic Treatments 40 rachoma, caused by infection with ocular strains Prevalence, % of chlamydia, is the leading infectious cause of 20 T blindness worldwide. The World Health Orga- nization recommends that in districts where the preva- lence of clinically active trachoma exceeds 10% in chil- 0 6 12 18 24 Time Since First Azithromycin Distribution, mo dren aged 1 to 9 years, communities should receive 3 annual mass antibiotic distributions followed by clini- cal reassessment; any communities with persistent tra- Figure. Prevalence of ocular chlamydial infection and clinically active trachoma in 24 Ethiopian villages. At months 0, 6, 12, and 18, mass choma should continue receiving annual mass antibi- azithromycin treatments were distributed subsequent to monitoring. Each otic treatments until the prevalence of clinically active solid gray line represents an individual village; the solid black line represents trachoma in children aged 1 to 9 years falls below 5%.1 the summary of all 24 villages (assessed by generalized estimating equation, Although trachoma treatment decisions are based on assuming the mean baseline prevalence of clinically active trachoma). the prevalence of clinically active trachoma, it is un- clear how quickly the clinical signs of trachoma resolve monitoring visits, using time and the log baseline preva- once infection has been cleared, especially in areas with lence of clinically active trachoma as fixed effects, vil- severe trachoma. We recently performed a series of cluster- lage as a random effect, a first-order autoregressive cor- randomized clinical trials for trachoma in an area of Ethio- relation structure, and the Huber-White sandwich estimate pia with hyperendemic trachoma. In these trials, infec- of variance. Use of the log-transformed outcome was de- tion was brought to a low level in 24 villages randomized cided a priori and was supported by plots of the residual to receive mass azithromycin treatments every 6 months. vs fitted values. Analyses were performed with Stata ver- This provided an opportunity to determine the rate of sion 10.0 statistical software (StataCorp LP, College Sta- resolution of the clinical signs of trachoma given little tion, Texas). to no chlamydial reinfection. Results. The mean prevalence of ocular chlamydial in- Methods. Twenty-four randomly selected villages re- fection in children before the baseline mass azithromy- ceived mass azithromycin treatment every 6 months for cin treatment was 52.9% (95% confidence interval, 44.2%- 18 months.2,3 In these villages, we monitored the preva- 61.3%) (Figure).4 Mass azithromycin distribution lence of ocular chlamydia and clinically active tra- subsequently occurred at months 0, 6, 12, and 18. The choma in all children aged 1 to 5 years 2 months after mean prevalence of ocular chlamydia in children dur- baseline and then every 6 months after baseline for 24 ing posttreatment biannual monitoring visits was 5.1% months. Monitoring preceded mass antibiotic treat- (95% confidence interval, 3.6%-6.6%). During these 24 ment at each of the biannual visits. Ocular chlamydial months, the prevalence of clinically active trachoma de- prevalence was assessed using maximum likelihood es- creased by 33.3% (95% confidence interval, 28.6%- timations from pooled chlamydial polymerase chain re- 38.0%) per year as estimated from the generalized esti- action (Amplicor; Roche Diagnostics, Branchburg, New mating equation (Figure). Jersey) as described previously.2,3 Clinically active tra- choma was defined as follicular trachoma and/or in- Comment. In a hyperendemic area, repeated biannual tense inflammatory trachoma according to the World mass antibiotic treatments reduced the level of ocular chla- Health Organization’s simplified grading system.1 Clini- mydial infection in children to a low level. The preva- cal examiners were trained and validated against gold- lence of the clinical signs of active trachoma declined at standard examiners as described previously.4 a much slower rate of 33.3% per year. This rate of reso- The primary outcome was the resolution rate of clini- lution is somewhat lower than that reported else- cally active trachoma at the village level. We used a gen- where.5,6 However, prior reports have been conducted in eralized estimating equation to predict the log preva- fewer villages, with less severe trachoma. In contrast, this lence of clinically active trachoma during biannual study was conducted in many villages in an area with se- (REPRINTED) ARCH OPHTHALMOL / VOL 129 (NO. 4), APR 2011 WWW.ARCHOPHTHALMOL.COM 512 ©2011 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/25/2021 vere trachoma and specifically included the variation among villages in the analysis. Furthermore, our analy- Intraocular Invasion by Microsporidial sis assessed the prevalence of clinically active trachoma Spores in a Case of Stromal Keratitis in a village as opposed to its presence in an individual. A village-level analysis is most useful for trachoma pro- icrobial keratitis is a visually disabling con- gram managers, who make treatment decisions based on dition caused by a variety of infectious organ- the prevalence of trachoma in a village. Our findings sug- isms. Although uncommon, microsporidial gest that in areas with hyperendemic trachoma treated M stromal keratitis has recently been reported as an emerg- through mass distribution of azithromycin, the signs of 1 active trachoma can be expected to resolve slowly, even ing cause of stromal keratitis. Intraocular microsporidi- if antibiotic distributions are quite successful in reduc- osis causing endophthalmitis and sclerouveitis with clear 2,3 ing the prevalence of ocular chlamydia. cornea has been reported, although there was no evi- dence of contiguous anterior chamber involvement. We Jeremy D. Keenan, MD, MPH report a rare case of microsporidial stromal keratitis in Takele Lakew, MD, MPH which microsporidial spores were detected from cor- Wondu Alemayehu, MD, MPH neal scraping, corneal tissue, and endothelial exudates. Muluken Melese, MD, MPH Jenafir I. House, MPH Report of a Case. A 40-year-old woman had intermit- Nisha R. Acharya, MD, MS tent pain, redness, photophobia, and decreased vision in Travis C. Porco, PhD, MPH her right eye for 1 year. She had trauma with a leaf 1 year Bruce D. Gaynor, MD before her initial visit to us. Since then, she had been Thomas M. Lietman, MD treated irregularly with topical antiviral medication (acy- clovir, 3%) by various health care providers. Author Affiliations: F. I. Proctor Foundation (Drs Keenan, On examination, her best-corrected visual acuity was Acharya, Porco, Gaynor, and Lietman and Ms House), Departments of Ophthalmology (Drs Keenan, Acharya, 20/70 OD. Slitlamp biomicroscopic examination of the Porco, Gaynor, and Lietman) and Epidemiology and Bio- right eye revealed conjunctival congestion, central stro- statistics (Drs Porco and Lietman), and Institute for Global mal edema with Descemet folds, and keratic precipi- Health (Dr Lietman), University of California, San Fran- tates (Figure, A). Her intraocular pressure was normal. cisco; and ORBIS International, Addis Ababa, Ethiopia Based on results of the clinical evaluation, a diagnosis of (Drs Lakew, Alemayehu, and Melese). herpetic viral endotheliitis was made. She began treat- Correspondence: Dr Keenan, F. I. Proctor Foundation ment with systemic acyclovir, 400 mg 5 times daily, and and Department of Ophthalmology, University of Cali- topical corticosteroid (prednisolone acetate, 1%). Al- fornia, San Francisco, 95 Kirkham St, San Francisco, CA though her visual acuity and clinical picture improved, 94143 ([email protected]). she revisited us 4.5 months after the initial visit with a Financial Disclosure: None reported. decrease in vision, tearing, and pain that had lasted 15 Funding/Support: This work was supported by grants K23 days. She was using topical steroid once every other day. EY019071 and U10 EY016214 from the National Insti- Her visual acuity was light perception with projection OD. tutes of Health, the Heed Ophthalmic Foundation, the In- There was a 3.8ϫ2.7-mm central full-thickness stro- ternational Trachoma Initiative, the Bernard Osher Foun- mal infiltrate. The endothelium showed exudates ar- dation, That Man May See, the Peierls Foundation, the Bodri ranged as a sheet. The corneal scrapings examined in po- Foundation, the Harper Inglis Trust, the South Asia Re- tassium hydroxide and calcofluor white mount (Figure, search Fund, and Research to Prevent Blindness. B) showed multiple oval microsporidial spores. The spores Additional Contributions: The Ethiopian Ministry of were also seen in Gram staining of the corneal scraping Health and many health care professionals, including (Figure, C). She began intensive treatment with topical Tadesse Kebede, Berhanu Fikre, Mifta Shifa, MPH, and polyhexamethylene biguanide, 0.02%, eyedrops. Ow- Tadesse Birru, helped us organize and implement our fieldwork in Ethiopia. ing to progressive thinning and descemetocele forma- tion (Figure, D), she underwent tissue adhesive appli- 1. Solomon AW, Zondervan M, Kuper H, Buchan JC, Mabey DCW, Foster A. cation 4 days later. After a week with no response to Trachoma Control: A Guide for Programme Managers. Geneva, Switzerland: medical therapy, she underwent therapeutic penetrat- World
Load more

Recommended publications
  • Vaccine to Prevent Human Papillomavirus
    Resolution No. 6/20-1 ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES VACCINES FOR CHILDREN PROGRAM VACCINES TO PREVENT MENINGOCOCCAL DISEASE The purpose of this resolution is to update the resolution to reflect currently available meningococcal conjugate vaccines that can be used to prevent meningococcal disease attributable to serogroups A, C, W, and Y. VFC resolution 6/19-7 is repealed and replaced by the following: Meningococcal Conjugate Vaccines (MenACWY) Eligible Groups • Children aged 2 months through 10 years who are at increased risk for meningococcal disease attributable to serogroups A, C, W, and Y, including: o Children who have persistent complement component deficiencies (including inherited or chronic deficiencies in C3, C5-C9, properdin, factor H, or factor D) o Children taking a complement inhibitor (e.g., eculizumab [Soliris], ravulizumab [Ultomiris]) o Children who have anatomic or functional asplenia, including sickle cell disease o Children infected with human immunodeficiency virus (HIV) o Children traveling to or residing in countries in which meningococcal disease is hyperendemic or epidemic, particularly if contact with local population will be prolonged o Children identified to be at increased risk because of a meningococcal disease outbreak attributable to serogroups A, C, W, or Y • All children aged 11 through 18 years 1 Recommended Vaccination Schedule and Intervals The table below lists meningococcal conjugate vaccines currently available to prevent meningococcal disease attributable to serogroups A, C, W, and
    [Show full text]
  • An Atlas of Potentially Water-Related Diseases in South Africa
    AN ATLAS OF POTENTIALLY WATER-RELATED DISEASES IN SOUTH AFRICA Volume 2 Bibliography Report to the WATER RESEARCH COMMISSION by N Coetzee and D E Bourne Department of Community Health University of Cape Town Medical School WRC Report no. 584/2/96 ISBN 1 86845 245 X ISBN Set No 1 86845 246 8 1 CONTENTS VOLUME 2 BIBLIOGRAPHY 1 Introduction 2 2 Amoebiasis 3 3 Arthropod-borne viral diseases 7 4 Cholera 10 5 Diarrhoeal diseases in childhood 14 6 Viral hepatitis A and E 17 7 Leptospirosis 20 3 Pediculosis 22 9 Malaria 23 10 Poliomyelitis 29 11 Scabies 33 12 Schistosomiasis 35 13 Trachoma 39 14 Typhoid Fever 42 15 Intestinal helminthiasis 46 1. INTRODUCTION As many professionals involved in the management of water resources do not have a medical or public health background, it was thought that an explanatory bibliography of the major water related diseases in South Africa would be of use. Each section of the bibliography has (where appropriate) the following sections: 1. Aetiology 2. Transmission 3. Preventive and curative steps 4. South African data 5. References The MEDLINE data base of the national Library of Medicine, Washington DC, and the WATERLIT data base of the CSIR were searched. These were supplemented by South African journals and reports not appearing in the MEDLINE data base. 3 2. AMOEBIASIS 2.1. Aetiology The protozoan parasite Entamoeba histolytica which causes amoebiasis may exist as a hardy infective cyst or a more fragile and potentially pathogenic trophozoite (the "amoebic" form). Amoebiasis most commonly affects the colon and rectum as primary sitas of infection, with extraintestinal (most commonly liver abscesses), local or systemic, spread possible if not treated early.
    [Show full text]
  • Comparison of Annual and Biannual Mass Antibiotic Administration for Elimination of Infectious Trachoma
    ORIGINAL CONTRIBUTION Comparison of Annual and Biannual Mass Antibiotic Administration for Elimination of Infectious Trachoma Muluken Melese, MD, MPH Context Treatment recommendations assume that repeated mass antibiotic distri- Wondu Alemayehu, MD, MPH butions can control, but not eradicate or even locally eliminate, the ocular strains of Takele Lakew, MD, MPH chlamydia that cause trachoma. Elimination may be an important end point because of concern that infection will return to communities that have lost immunity to chla- Elizabeth Yi, MPH mydia after antibiotics are discontinued. Jenafir House, MPH, MSW Objective To determine whether biannual treatment can eliminate ocular chla- Jaya D. Chidambaram, MBBS mydial infection from preschool children and to compare results with the World Health Organization–recommended annual treatment. Zhaoxia Zhou, BA Design, Setting, and Participants A cluster-randomized clinical trial of biannual Vicky Cevallos, MT vs annual mass azithromycin administrations to all residents of 16 rural villages in the Kathryn Ray, MA Gurage Zone, Ethiopia, from March 2003 to April 2005. Kevin Cyrus Hong, BA Interventions At scheduled treatments, all individuals aged 1 year or older were Travis C. Porco, PhD, MPH offered a single dose of oral azithromycin either annually or biannually. Isabella Phan, MD Main Outcome Measure Village prevalence of ocular chlamydial infection and pres- ence of elimination at 24 months in preschool children determined by polymerase chain Ali Zaidi, MD reaction, correcting for baseline prevalence. Antibiotic treatments were performed af- Bruce D. Gaynor, MD ter sample collections. John P. Whitcher, MD, MPH Results Overall, 14 897 of 16 403 eligible individuals (90.8%) received their sched- uled treatment.
    [Show full text]
  • The Emergence of Epidemic Dengue Fever and Dengue Hemorrhagic
    Editorial The emergence of A global pandemic of dengue fever (DF) and dengue hemorrhagic fever (DHF) began in Southeast Asia during World War II and in the years following that con- epidemic dengue flict (1). In the last 25 years of the 20th century the pandemic intensified, with increased geographic spread of both the viruses and the principal mosquito vec- fever and dengue tor, Aedes aegypti. This led to larger and more frequent epidemics and to the emergence of DHF as tropical countries and regions became hyperendemic with hemorrhagic fever the co-circulation of multiple virus serotypes. With the exception of sporadic epidemics in the Caribbean islands, in the Americas: dengue and yellow fever were effectively controlled in the Americas from 1946 a case of failed until the late 1970s as a result of the Ae. aegypti eradication program conducted by the Pan American Health Organization (PAHO) (1, 2). This was a vertically struc- public health policy tured, paramilitary program that focused on mosquito larval control using source reduction and use of insecticides, primarily dichlorodiphenyltrichloroethane (DDT). This highly successful program, however, was disbanded in the early 1970s because there was no longer a perceived need and there were competing 1 Duane Gubler priorities for resources; control of dengue and yellow fever was thereafter merged with malaria control. Another major policy change at that time was the use of ultra-low-volume space sprays for killing adult mosquitoes (adulticides) as the rec- ommended method to control Ae. aegypti and thus prevent and control DF and DHF. Both of these decisions were major policy failures because they were inef- fective in preventing the re-emergence of epidemic DF and the emergence of DHF in the Region.
    [Show full text]
  • Meeting of the Board of Scientific Counselors, Office of Infectious Diseases
    MEETING OF THE BOARD OF SCIENTIFIC COUNSELORS, OFFICE OF INFECTIOUS DISEASES Centers for Disease Control and Prevention Tom Harkin Global Communications Center Atlanta, Georgia May 2–3, 2018 A one-and-a-half day, open public meeting of the Board of Scientific Counselors (BSC), Office of Infectious Diseases (OID), was held on May 2–3, 2018, at the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia. In addition to Board members and CDC staff, the meeting was attended by representatives of several public health partner organizations (appendix). The meeting included • Updates from OID, the Center for Global Health (CGH), and the National Centers for Immunization and Respiratory Diseases (NCIRD); HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP); and Emerging and Zoonotic Infectious Diseases (NCEZID) • Updates from the BSC Infectious Disease Laboratory Working Group (IDLWG) and the new OID– National Center for Environmental Health (NCEH)/Agency for Toxic Substances and Disease Registry (ATSDR) Vector-borne Diseases Workgroup • Updates on activities to address antimicrobial resistance by Veterinary Services (VS), Animal and Plant Health Inspection Service, U.S. Department of Agriculture (USDA/APHIS) and CDC • Presentations and discussion about CDC efforts to address the opioid epidemic, train the next generation of public health workers, and advance the CDC High Containment Laboratory Initiative The meeting also included a conversation with CDC Director Robert Redfield. Opening Remarks BSC Chair Ruth Lynfield, State Epidemiologist and Medical Director, Minnesota Department of Health, called the meeting to order and was joined in welcoming participants and facilitating introductions by Sonja Rasmussen, CDC Deputy Director for Infectious Diseases, and Sarah Wiley, the BSC/OID Designated Federal Official.
    [Show full text]
  • Waterborne Disease Risk Assessment Program 2019 Annual Report
    New York City Department of Health & Mental Hygiene Bureau of Communicable Disease & New York City Department of Environmental Protection Bureau of Water Supply Waterborne Disease Risk Assessment Program 2019 Annual Report March 2020 Prepared in accordance with Section 8.1 of the NYSDOH 2017 NYC Filtration Avoidance Determination i TABLE OF CONTENTS TABLE OF CONTENTS ................................................................................................................. i LIST OF TABLES ........................................................................................................................ iii LIST OF FIGURES ........................................................................................................................ iv LIST OF ACRONYMS ................................................................................................................... v ACKNOWLEDGMENTS .............................................................................................................. vi EXECUTIVE SUMMARY .......................................................................................................... vii 1. INTRODUCTION .................................................................................................................... 1 2. DISEASE SURVEILLANCE .................................................................................................. 1 2.1 Giardiasis .......................................................................................................................... 1
    [Show full text]
  • Recommended Adult Immunization Schedule
    Recommended Adult Immunization Schedule UNITED STATES for ages 19 years or older 2021 Recommended by the Advisory Committee on Immunization Practices How to use the adult immunization schedule (www.cdc.gov/vaccines/acip) and approved by the Centers for Disease Determine recommended Assess need for additional Review vaccine types, Control and Prevention (www.cdc.gov), American College of Physicians 1 vaccinations by age 2 recommended vaccinations 3 frequencies, and intervals (www.acponline.org), American Academy of Family Physicians (www.aafp. (Table 1) by medical condition and and considerations for org), American College of Obstetricians and Gynecologists (www.acog.org), other indications (Table 2) special situations (Notes) American College of Nurse-Midwives (www.midwife.org), and American Academy of Physician Assistants (www.aapa.org). Vaccines in the Adult Immunization Schedule* Report y Vaccines Abbreviations Trade names Suspected cases of reportable vaccine-preventable diseases or outbreaks to the local or state health department Haemophilus influenzae type b vaccine Hib ActHIB® y Clinically significant postvaccination reactions to the Vaccine Adverse Event Hiberix® Reporting System at www.vaers.hhs.gov or 800-822-7967 PedvaxHIB® Hepatitis A vaccine HepA Havrix® Injury claims Vaqta® All vaccines included in the adult immunization schedule except pneumococcal 23-valent polysaccharide (PPSV23) and zoster (RZV) vaccines are covered by the Hepatitis A and hepatitis B vaccine HepA-HepB Twinrix® Vaccine Injury Compensation Program. Information on how to file a vaccine injury Hepatitis B vaccine HepB Engerix-B® claim is available at www.hrsa.gov/vaccinecompensation. Recombivax HB® Heplisav-B® Questions or comments Contact www.cdc.gov/cdc-info or 800-CDC-INFO (800-232-4636), in English or Human papillomavirus vaccine HPV Gardasil 9® Spanish, 8 a.m.–8 p.m.
    [Show full text]
  • Immigration IZ– a Resource for Healthcare Providers
    Immigration IZ– A resource for healthcare providers Vaccines required for immigration applications should be age appropriate. 1 For example, if the applicant is 35 2 years of age, then he or she is required to receive tetanus and diphtheria toxoids vaccine (Td) or tetanus and 3 diphtheria toxoids and acellular pertus- sis vaccine (Tdap), MMR, and varicella 4 (if no history of varicella disease). If 5 the applicant had previously received a dose or doses of a required vaccine but 6 had not completed the series, then the next required dose should be adminis- 7 tered according to standard ACIP rec- ommendations. 8 Can still recommend other vaccinations 9 based on risk factors, but they are not required. 10 11 Please note that HPV and Zoster are not a requirement for immigration 12 1. A fifth dose of DTaP vaccine is not necessary if the fourth dose was administered at age 4 years or older. 2. Tdap for all pregnant women. Adults with incomplete vaccination will receive remaining doses. Adults with unknown history of vaccination will receive 3 doses (Tdap for first dose; remaning doses and boosters with Td) 3. A fourth dose of polio is not necessary if the third dose was administered at age 4 years or older and at least 6 months after the previous dose. ministered as part of a series, a total of 4 doses should be administered, regardless of the child’s current age 4. Documentation of provider-diagnosed disease is not considered acceptable evidence of immunity for measles, mumps, or rubella. Need at least one dose.
    [Show full text]
  • Sexually Transmitted Infections Treatment Guidelines, 2021
    Morbidity and Mortality Weekly Report Recommendations and Reports / Vol. 70 / No. 4 July 23, 2021 Sexually Transmitted Infections Treatment Guidelines, 2021 U.S. Department of Health and Human Services Centers for Disease Control and Prevention Recommendations and Reports CONTENTS Introduction ............................................................................................................1 Methods ....................................................................................................................1 Clinical Prevention Guidance ............................................................................2 STI Detection Among Special Populations ............................................... 11 HIV Infection ......................................................................................................... 24 Diseases Characterized by Genital, Anal, or Perianal Ulcers ............... 27 Syphilis ................................................................................................................... 39 Management of Persons Who Have a History of Penicillin Allergy .. 56 Diseases Characterized by Urethritis and Cervicitis ............................... 60 Chlamydial Infections ....................................................................................... 65 Gonococcal Infections ...................................................................................... 71 Mycoplasma genitalium .................................................................................... 80 Diseases Characterized
    [Show full text]
  • Sexually Transmitted Diseases Treatment Guidelines, 2015
    Morbidity and Mortality Weekly Report Recommendations and Reports / Vol. 64 / No. 3 June 5, 2015 Sexually Transmitted Diseases Treatment Guidelines, 2015 U.S. Department of Health and Human Services Centers for Disease Control and Prevention Recommendations and Reports CONTENTS CONTENTS (Continued) Introduction ............................................................................................................1 Gonococcal Infections ...................................................................................... 60 Methods ....................................................................................................................1 Diseases Characterized by Vaginal Discharge .......................................... 69 Clinical Prevention Guidance ............................................................................2 Bacterial Vaginosis .......................................................................................... 69 Special Populations ..............................................................................................9 Trichomoniasis ................................................................................................. 72 Emerging Issues .................................................................................................. 17 Vulvovaginal Candidiasis ............................................................................. 75 Hepatitis C ......................................................................................................... 17 Pelvic Inflammatory
    [Show full text]
  • Scientific Collections and Emerging Infectious Diseases: Report of an Interdisciplinary Workshop
    Scientific Collections International Report (1) March 2015 Scientific Collections and Emerging Infectious Diseases: Report of an Interdisciplinary Workshop Phase 1: Detection OUTBREAK Phase 4: Prediction Phase 2: Characterization Phase 3: Mitigation Sc Scientific Collections International Scientific Collections International (SciColl) is a global consortium devoted to promoting the use and impact of object-based scientific collections across disciplines. SciColl’s member countries and institutions own and manage collections of objects used for research in archaeology, biology, biomedicine, earth and space sciences, technology, and other fields. SciColl’s mission is to increase the return on investment that countries and institutions make in their scientific collections by catalyzing international and interdisciplinary collaboration. Emerging Infectious Diseases, Food Security, Environmental Change, and Human Migration are the four research initiatives identified by SciColl for demonstrating the interdisciplinary value and impact of collections. SciColl is also developing an online Global Registry of Scientific Collections to increase access to information across disciplinary boundaries. This document presents a report of SciColl’s first activity in the area of Emerging Infectious Diseases. The workshop was designed by the Steering Committee: Diane diEuliis, Richard Jaffe, Manuela da Silva, Richard P. Lane, Tim Littlewood, Eileen Graham, and David E. Schindel, assisted by Adele Crane and Franco Ciammachilli. This report is a written record of the workshop presentations and discussions as compiled by the Steering Committee with input from the entire field of participants. A full list of workshop participants and their institutional affiliations can be found in the Appendix. Suggested Citation Scientific Collections International (2015 March). Scientific Collections and Emerging Infectious Diseases: Report of an Interdisciplinary Workshop.
    [Show full text]
  • CHAPTER 4 Infectious Disease
    CHAPTER 4 Infectious Disease 99 | Massachusetts State Health Assessment Infectious Disease This chapter provides information on preventing and controlling infectious diseases, and related trends, disparities, and resources in the Commonwealth of Massachusetts. It addresses the following infectious disease topic areas: • Foodborne Diseases • Healthcare-Associated Infections • Sexually Transmitted Infections • Human Immunodeficiency Virus • Viral Hepatitis • Tuberculosis • Vectorborne Diseases • Immunization • Selected Resources, Services, and Programs Chapter Data Highlights • Over 4,200 confirmed cases of foodborne disease in 2015 • HIV infections decreased by 31% from 2005 to 2014 • In 2015, hepatitis C case rates were 26 and 10 times higher, respectively, among White non-Hispanics compared to Asian non-Hispanics and Black non-Hispanics • In 2016, 190 cases of TB were reported in Massachusetts • Tickborne babesiosis increased 15% from 2015 to 2016 • Influenza and pneumonia ranked in the top ten leading causes of death among Massachusetts residents in 2014 100 | Massachusetts State Health Assessment Overview Infectious diseases have been causing human illness and death since the dawn of human existence. The effective prevention and control of these diseases is one of the major reasons for increases in life expectancy. In 1701, Massachusetts passed legislation requiring the isolation of the sick “for better preventing the spread of infection.”190 Since then, Massachusetts has led the nation in infection prevention and control. For example, Massachusetts was the only state to achieve a score of 10 out of 10 in Health Security Ranking which includes reducing healthcare-associated infections (HAIs), biosafety training in public health laboratories, public health funding commitment, national health security preparedness, public health accreditation, flu vaccination rates, climate change readiness,afety as well as a biosafety professional on staff and emergency health care access.
    [Show full text]